Corona Remedies Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/itgs3w292xfzvjzww2wd7jxc.pdf

Key Takeaways


Growth Engine: Volume, Pricing & Portfolio

Nirav Mehta: "I was anticipating this since last 6 months, that by November-December, industry will start giving the double-digit growth, and this is sustainable for at least a year, because that has been anticipated in the mind."

Acquisitions: Wokadine & Bayer Zydus Portfolio

Bhavin Bhagat: "I always tell to our investors that we are a net cash company... we don't have any single cash credit facility from any banks. We avail the facility, but we don't use it at the end of the day."

Margin Bridge: Investment Today, Operating Leverage Tomorrow


Biosimilars, Manufacturing & International

Nirav Mehta: "My own understanding is, and the calculation is if in India there are about 10 crore eligible patients for the Semaglutide market and if conversion ratio is about 2%-3% and the therapy cost, if you calculate, I think the first year may be a year of INR 2,000 crore to INR 2,500 crore as the Semaglutide market."

Sales Force, Productivity & AI Tools


Guidance & Commitments

CommitmentSpecificsTimeline
Organic revenue growth15%+ annually (domestic and international combined)FY27 and next 3–5 years
Acquired portfolio revenue growth25% revenue growth on Wokadine and Bayer Zydus portfolioFY27 and next 2–3 years
PAT growth20%+ annuallyFY27 and next 3–5 years
Gross margin floorSustain at ~80%Coming years
Wokadine revenue growth25% annuallyAt least 3–4 years
Hormone manufacturing plantOperationalQ1 or Q2 FY27
Myoril long-term loanFully repaidThis year (FY27)
International Bhayla plant revenue contributionProduct registration takes ~1.5–2 years; meaningful revenue thereafter2–3 years out

Key Metrics

MetricQ4 FY26
Revenue₹353 cr, +20.2% YoY
Domestic revenue growth18.3% YoY
International revenue growth70% YoY
EBITDA₹62 cr, +14.4% YoY
EBITDA margin17.6%, declined ~90 bps YoY; impacted by ~₹14 cr in employee-related costs for two new divisions and ~₹1.6 cr in R&D spend
PAT₹45 cr, +44% YoY
FY26 revenue₹1,403 cr, +17.3% YoY
FY26 EBITDA₹293 cr, +22.3% YoY
FY26 EBITDA margin20.9%, improved ~80 bps YoY
FY26 adjusted PAT₹199 cr, +33.4% YoY (excluding one-time labour code changes)
FY26 gross margin81.4%
FY26 India business share96% of total revenue
FY26 chronic segment contribution71.9% of revenue
FY26 volume growth3%, 4.6x IPM volume growth of 0.7%
FY26 new product launch growth6.4%, 2.6x IPM new product growth of 2.5%
FY26 cash flow from operations~₹229 cr, CFO to EBITDA conversion at ~78%
FY26 RoCE~41%
FY26 RoE29.2%
MR strength3,100, net addition of 450 in FY26
PCPM₹4.11 lakhs per month, up from ₹3.62 lakhs last year
Brands in ₹100–₹200 cr club2 brands
Brands in ₹50–₹100 cr club8 brands
IPM industry ranking27th, improved five spots in last three years
FY27 organic revenue growth guidance15%+
FY27 acquired portfolio revenue growth guidance25%
FY27 PAT growth guidance20%+
Dividend for FY26₹10 per share, 100% dividend